- Home
- PVLA vs STDN Comparison
PVLA vs STDN Comparison
Compare PVLA & STDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PVLA | STDN |
|---|---|---|
| Founded | 2015 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2013 | 2026 |
Fundamental Metrics
Financial Performance| Metric | PVLA | STDN |
|---|---|---|
| Price | $152.42 | $12.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 9 |
| Target Price | ★ $228.40 | $17.25 |
| AVG Volume (30 Days) | 196.9K | ★ 267.8K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.62 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $42,810,000.00 | N/A |
| Revenue This Year | N/A | $439.23 |
| Revenue Next Year | N/A | $259.21 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 65.28 | N/A |
| 52 Week Low | $72.23 | $7.05 |
| 52 Week High | $161.38 | $17.34 |
Technical Indicators
Market Signals| Indicator | PVLA | STDN |
|---|---|---|
| Relative Strength Index (RSI) | 62.72 | 47.31 |
| Support Level | $145.91 | $11.42 |
| Resistance Level | $158.60 | $13.73 |
| Average True Range (ATR) | 7.36 | 0.77 |
| MACD | 3.42 | -0.04 |
| Stochastic Oscillator | 84.42 | 50.28 |
Price Performance
Historical ComparisonAbout PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
About STDN Standard Nuclear Inc. Class A Common Stock
Standard Nuclear Inc is an independent advanced nuclear fuel company. The company designs, engineers, and manufactures advanced nuclear fuels, with a primary focus on TRISO fuel for advanced reactors. Its operations include industrial-scale TRISO fuel manufacturing and the development of fuel for advanced reactors that utilize TRISO fuel. The company operates in a single operating and reportable segment, as it is engaged in a single business activity of TRISO production. It derives revenue from fuel development and services agreements. Geographically, the maximum revenue is generated from the United States.